Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach

Allergan ($AGN) is adding to its dry-eye lineup with a new purchase agreement. The company has bet $125 million on a new approach to the disease, picking up Oculeve and lead candidate OD-01--a nerve-stimulating implant placed in the nose. More from FierceBiotech